ProfileGDS5678 / 1452282_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 58% 58% 59% 55% 56% 56% 58% 58% 59% 58% 59% 58% 58% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5174457
GSM967853U87-EV human glioblastoma xenograft - Control 23.5075158
GSM967854U87-EV human glioblastoma xenograft - Control 33.500958
GSM967855U87-EV human glioblastoma xenograft - Control 43.4784959
GSM967856U87-EV human glioblastoma xenograft - Control 53.3193955
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5245456
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5034456
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4928958
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4872758
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5057559
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.490958
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5179859
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5006358
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4962858